IRWD - Comprehensive Filing Intelligence

FY•10-K•Filed Feb 26, 2026
6.0/10
Filing Health:GOOD

Solid fundamentals with minor concerns to monitor

Executive Summary

The company is advancing apraglutide through clinical trials, with a confirmatory Phase III trial (STARS-2) planned, though regulatory approval remains uncertain.. Settled litigation regarding apraglutide technology rights with Ferring International Center S.A. involved claims of trade secret misappropriation and patent disputes.. Revenue decreased by 15.7% to $296.2 million in 2025 from $351.4 million in 2024.

Top Concerns

  • !Settled litigation regarding apraglutide technology rights with Ferring International Center S.A. involved claims of trade secret misappropriation and patent disputes.
  • !Dependence on LINZESS commercial success (high)
  • !Product Development and Regulatory Approval Risk (Apraglutide) (medium)

Top Positives

  • +Total revenues decreased in 2025 compared to 2024, driven by lower net price and inventory fluctuations for LINZESS, partially offset by increased prescription demand.
  • +Income from operations improved due to a significant $60.6 million decrease in operating expenses, largely from restructuring activities in 2025.
  • +Operating cash flow increased to $127.0 million in 2025, primarily from LINZESS-related revenue, indicating strong operational cash generation.

Analysis Dimensions

Our 5-pass AI analysis examines this filing across multiple dimensions. Each dimension score is derived from direct analysis of SEC filing text.

Narrative Intelligence

6.0/10

Management tone is balanced.

Full analysis includes: tone changes vs prior quarter, margin driver breakdown, forward guidance analysis, strategic priorities.

Accounting Quality

8.0/10

Earnings quality shows conservative accounting practices.

Full analysis includes: reserve and allowance changes, non-recurring item analysis, stock-based compensation impact, disclosure concerns.

Hidden Liabilities

Off-balance sheet risk is low.

Full analysis includes: cloud and purchase commitments, VIE/SPE exposure, covenant compliance status, refinancing risk assessment.

Risk Landscape

6.0/10

Overall risk profile shows dependence on linzess commercial success as primary concern.

Full analysis includes: 8 risk categories with severity, new vs escalated risks, management response assessment, risk trend analysis.

Segment Performance

4.0/10

Segment health analysis.

Full analysis includes: segment-by-segment revenue breakdown, geographic concentration risk, customer concentration analysis, segment margin trends.